Published in Nat Rev Cancer on May 01, 2008
Therapeutic Response Evaluation by CTC Expansion System | NCT04972461
Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science (2013) 10.87
Tumor metastasis: molecular insights and evolving paradigms. Cell (2011) 10.34
EMT and dissemination precede pancreatic tumor formation. Cell (2012) 9.27
Circulating tumor cells: approaches to isolation and characterization. J Cell Biol (2011) 6.54
Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst (2008) 5.74
Parallel progression of primary tumours and metastases. Nat Rev Cancer (2009) 5.55
Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. J Clin Oncol (2015) 5.48
Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci Transl Med (2013) 4.74
Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res (2009) 3.76
Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS One (2012) 3.74
Cancer micrometastases. Nat Rev Clin Oncol (2009) 3.69
To differentiate or not--routes towards metastasis. Nat Rev Cancer (2012) 3.59
Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer (2009) 3.46
Circulating clonotypic B cells in classic Hodgkin lymphoma. Blood (2009) 3.34
In vivo magnetic enrichment and multiplex photoacoustic detection of circulating tumour cells. Nat Nanotechnol (2009) 3.21
Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device. Proc Natl Acad Sci U S A (2009) 3.19
Highly efficient capture of circulating tumor cells by using nanostructured silicon substrates with integrated chaotic micromixers. Angew Chem Int Ed Engl (2011) 2.79
Circulating tumor cells from well-differentiated lung adenocarcinoma retain cytomorphologic features of primary tumor type. Arch Pathol Lab Med (2009) 2.73
Tumor metastasis: moving new biological insights into the clinic. Nat Med (2013) 2.71
Bioorthogonal chemistry amplifies nanoparticle binding and enhances the sensitivity of cell detection. Nat Nanotechnol (2010) 2.49
Molecular biomarker analyses using circulating tumor cells. PLoS One (2010) 2.38
Isolation and retrieval of circulating tumor cells using centrifugal forces. Sci Rep (2013) 2.30
Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst (2014) 2.28
Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors. Genes Chromosomes Cancer (2010) 2.11
3D microfilter device for viable circulating tumor cell (CTC) enrichment from blood. Biomed Microdevices (2011) 2.10
Tumor cell dissemination: emerging biological insights from animal models and cancer patients. Cancer Cell (2013) 2.08
Epithelial to mesenchymal transition and breast cancer. Breast Cancer Res (2009) 2.05
Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer. Int J Cancer (2011) 2.02
Detection and differentiation of normal, cancerous, and metastatic cells using nanoparticle-polymer sensor arrays. Proc Natl Acad Sci U S A (2009) 2.02
Considerations in the development of circulating tumor cell technology for clinical use. J Transl Med (2012) 2.00
End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. J Clin Oncol (2011) 1.94
Occult metastases in lymph nodes predict survival in resectable non-small-cell lung cancer: report of the ACOSOG Z0040 trial. J Clin Oncol (2011) 1.93
Sensitive capture of circulating tumour cells by functionalized graphene oxide nanosheets. Nat Nanotechnol (2013) 1.92
The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells. Cancer Cell (2015) 1.91
Metastatic stem cells: sources, niches, and vital pathways. Cell Stem Cell (2014) 1.88
Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device. PLoS One (2012) 1.86
Three-dimensional nanostructured substrates toward efficient capture of circulating tumor cells. Angew Chem Int Ed Engl (2009) 1.86
Cancer stem cell-directed therapies: recent data from the laboratory and clinic. Mol Ther (2008) 1.83
Mechanisms governing metastatic dormancy and reactivation. Cell (2013) 1.81
Microfluidic, marker-free isolation of circulating tumor cells from blood samples. Nat Protoc (2014) 1.80
HER2-positive circulating tumor cells in breast cancer. PLoS One (2011) 1.73
Controversies in clinical cancer dormancy. Proc Natl Acad Sci U S A (2011) 1.71
Single-cell RNA sequencing identifies extracellular matrix gene expression by pancreatic circulating tumor cells. Cell Rep (2014) 1.69
Cytomorphology of circulating colorectal tumor cells:a small case series. J Oncol (2010) 1.66
High-performance single cell genetic analysis using microfluidic emulsion generator arrays. Anal Chem (2010) 1.64
Aptamer-based microfluidic device for enrichment, sorting, and detection of multiple cancer cells. Anal Chem (2009) 1.61
Strategies for the discovery and development of therapies for metastatic breast cancer. Nat Rev Drug Discov (2012) 1.61
Notch promotes recurrence of dormant tumor cells following HER2/neu-targeted therapy. J Clin Invest (2015) 1.58
Integrated EpCAM-independent subtraction enrichment and iFISH strategies to detect and classify disseminated and circulating tumors cells. Clin Transl Med (2015) 1.45
A microfluidic device for label-free, physical capture of circulating tumor cell clusters. Nat Methods (2015) 1.43
Rare cell separation and analysis by magnetic sorting. Anal Chem (2011) 1.41
Retracted Activation of miR-31 function in already-established metastases elicits metastatic regression. Genes Dev (2011) 1.40
Detection of circulating tumor cells in human peripheral blood using surface-enhanced Raman scattering nanoparticles. Cancer Res (2011) 1.36
Comparison of bone marrow, disseminated tumour cells and blood-circulating tumour cells in breast cancer patients after primary treatment. Br J Cancer (2008) 1.34
Clinical relevance and biology of circulating tumor cells. Breast Cancer Res (2011) 1.34
"Sentinel" circulating tumor cells allow early diagnosis of lung cancer in patients with chronic obstructive pulmonary disease. PLoS One (2014) 1.34
Isolation of circulating epithelial and tumor progenitor cells with an invasive phenotype from breast cancer patients. Int J Cancer (2010) 1.31
Clinical opportunities and challenges in targeting tumour dormancy. Nat Rev Clin Oncol (2012) 1.26
Circulating tumor cell analysis: technical and statistical considerations for application to the clinic. J Oncol (2009) 1.26
Full-length cytokeratin-19 is released by human tumor cells: a potential role in metastatic progression of breast cancer. Breast Cancer Res (2009) 1.25
Circulating tumors cells as biomarkers: progress toward biomarker qualification. Cancer J (2011) 1.25
Capture, release and culture of circulating tumor cells from pancreatic cancer patients using an enhanced mixing chip. Lab Chip (2013) 1.23
Early diagnosis of pancreatic cancer: challenges and new developments. Biomark Med (2012) 1.23
Bioinspired multivalent DNA network for capture and release of cells. Proc Natl Acad Sci U S A (2012) 1.21
Polymer nanofiber-embedded microchips for detection, isolation, and molecular analysis of single circulating melanoma cells. Angew Chem Int Ed Engl (2013) 1.21
Confocal images of circulating tumor cells obtained using a methodology and technology that removes normal cells. Mol Pharm (2009) 1.20
Array-based sensing with nanoparticles: 'chemical noses' for sensing biomolecules and cell surfaces. Curr Opin Chem Biol (2010) 1.20
Relevance of PTEN loss in brain metastasis formation in breast cancer patients. Breast Cancer Res (2012) 1.20
Blood salvage and cancer surgery: should we do it? Transfusion (2009) 1.19
Nanowire substrate-based laser scanning cytometry for quantitation of circulating tumor cells. Nano Lett (2012) 1.19
Validation and clinical utility of prostate cancer biomarkers. Nat Rev Clin Oncol (2013) 1.17
Phenotypic characterization of disseminated cells with TSC2 loss of heterozygosity in patients with lymphangioleiomyomatosis. Am J Respir Crit Care Med (2010) 1.17
Identification of luminal breast cancers that establish a tumor-supportive macroenvironment defined by proangiogenic platelets and bone marrow-derived cells. Cancer Discov (2012) 1.16
Capture and stimulated release of circulating tumor cells on polymer-grafted silicon nanostructures. Adv Mater (2012) 1.16
Luminal breast cancer: from biology to treatment. Nat Rev Clin Oncol (2013) 1.16
Heterogeneity of estrogen receptor expression in circulating tumor cells from metastatic breast cancer patients. PLoS One (2013) 1.16
Negative enrichment by immunomagnetic nanobeads for unbiased characterization of circulating tumor cells from peripheral blood of cancer patients. J Transl Med (2011) 1.15
Metastasis dormancy in estrogen receptor-positive breast cancer. Clin Cancer Res (2013) 1.15
Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer. BMC Cancer (2012) 1.13
Isolation of tumorigenic circulating melanoma cells. Biochem Biophys Res Commun (2010) 1.13
Specific capture and release of circulating tumor cells using aptamer-modified nanosubstrates. Adv Mater (2013) 1.13
Analytic and clinical validation of a prostate cancer-enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival. Eur Urol (2013) 1.12
Genomic profiling of isolated circulating tumor cells from metastatic breast cancer patients. Cancer Res (2012) 1.12
Dynamic physical properties of dissociated tumor cells revealed by dielectrophoretic field-flow fractionation. Integr Biol (Camb) (2011) 1.11
Efficient capture of circulating tumor cells with a novel immunocytochemical microfluidic device. Biomicrofluidics (2011) 1.11
Emerging technologies for CTC detection based on depletion of normal cells. Recent Results Cancer Res (2012) 1.09
Nanoroughened surfaces for efficient capture of circulating tumor cells without using capture antibodies. ACS Nano (2012) 1.08
Expansion of CTCs from early stage lung cancer patients using a microfluidic co-culture model. Oncotarget (2014) 1.08
Isolation and mutational analysis of circulating tumor cells from lung cancer patients with magnetic sifters and biochips. Lab Chip (2014) 1.07
Comparative evaluation of cell-free tumor DNA in blood and disseminated tumor cells in bone marrow of patients with primary breast cancer. Breast Cancer Res (2009) 1.06
Circulating tumor cells and DNA as liquid biopsies. Genome Med (2013) 1.06
Multivalent DNA nanospheres for enhanced capture of cancer cells in microfluidic devices. ACS Nano (2013) 1.05
Pathology: are circulating tumor cells predictive of overall survival? Nat Rev Clin Oncol (2009) 1.05
Squamous cell carcinoma of the oral cavity and circulating tumour cells. World J Clin Oncol (2014) 1.02
Continual collection and re-separation of circulating tumor cells from blood using multi-stage multi-orifice flow fractionation. Biomicrofluidics (2013) 1.02
Blood and tissue biomarkers in prostate cancer: state of the art. Urol Clin North Am (2010) 1.02
Quantitative ratiometric discrimination between noncancerous and cancerous prostate cells based on neuropilin-1 overexpression. Proc Natl Acad Sci U S A (2011) 1.02
Herceptin functionalized microfluidic polydimethylsiloxane devices for the capture of human epidermal growth factor receptor 2 positive circulating breast cancer cells. Biomicrofluidics (2010) 1.02
Single-cell technologies are revolutionizing the approach to rare cells. Immunol Cell Biol (2015) 1.01
Genetically abnormal circulating cells in lung cancer patients: an antigen-independent fluorescence in situ hybridization-based case-control study. Clin Cancer Res (2010) 1.01
The molecular biology of head and neck cancer. Nat Rev Cancer (2010) 9.84
MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene (2003) 7.90
Dissecting the metastatic cascade. Nat Rev Cancer (2004) 6.32
A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res (2003) 5.04
A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer (2007) 4.29
Cancer micrometastases. Nat Rev Clin Oncol (2009) 3.69
Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. J Natl Cancer Inst (2004) 3.67
BAC to the future! or oligonucleotides: a perspective for micro array comparative genomic hybridization (array CGH). Nucleic Acids Res (2006) 3.32
Common adult stem cells in the human breast give rise to glandular and myoepithelial cell lineages: a new cell biological concept. Lab Invest (2002) 2.33
Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest (2002) 2.06
HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin Cancer Res (2006) 1.93
Second primary tumors and field cancerization in oral and oropharyngeal cancer: molecular techniques provide new insights and definitions. Head Neck (2002) 1.41
Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature. BMC Cancer (2008) 1.37
Clinical and molecular characteristics of squamous cell carcinomas from Fanconi anemia patients. J Natl Cancer Inst (2008) 1.36
A genetic progression model of oral cancer: current evidence and clinical implications. J Oral Pathol Med (2004) 1.36
Advances and applications of oral cancer basic research. Oral Oncol (2011) 1.33
Increasing prevalence rates of HPV attributable oropharyngeal squamous cell carcinomas in the Netherlands as assessed by a validated test algorithm. Int J Cancer (2012) 1.31
Cytokeratin 8/18 expression indicates a poor prognosis in squamous cell carcinomas of the oral cavity. BMC Cancer (2006) 1.28
Molecular diagnosis of surgical margins and local recurrence in head and neck cancer patients: a prospective study. Clin Cancer Res (2004) 1.24
CGHMultiArray: exact P-values for multi-array comparative genomic hybridization data. Bioinformatics (2005) 1.23
Multiple head and neck tumors frequently originate from a single preneoplastic lesion. Am J Pathol (2002) 1.20
Expanding fields of genetically altered cells in head and neck squamous carcinogenesis. Semin Cancer Biol (2005) 1.20
Genomic profiles associated with early micrometastasis in lung cancer: relevance of 4q deletion. Clin Cancer Res (2009) 1.19
Genetically altered fields as origin of locally recurrent head and neck cancer: a retrospective study. Clin Cancer Res (2004) 1.18
Human papilloma virus in head and neck cancer: the need for a standardised assay to assess the full clinical importance. Eur J Cancer (2009) 1.14
Comparative molecular and histological grading of epithelial dysplasia of the oral cavity and the oropharynx. J Pathol (2003) 1.13
Pro-inflammatory wnt5a and anti-inflammatory sFRP5 are differentially regulated by nutritional factors in obese human subjects. PLoS One (2012) 1.13
Asynchronous growth of prostate cancer is reflected by circulating tumor cells delivered from distinct, even small foci, harboring loss of heterozygosity of the PTEN gene. Cancer Res (2006) 1.13
Characterization of the human Ly-6 antigens, the newly annotated member Ly-6K included, as molecular markers for head-and-neck squamous cell carcinoma. Int J Cancer (2003) 1.12
HIF1-alpha overexpression indicates a good prognosis in early stage squamous cell carcinomas of the oral floor. BMC Cancer (2005) 1.12
Generation and molecular characterization of head and neck squamous cell lines of fanconi anemia patients. Cancer Res (2005) 1.12
Mutated p53 as a molecular marker for the diagnosis of head and neck cancer. J Pathol (2002) 1.11
Distinct amplification of an untranslated regulatory sequence in the egfr gene contributes to early steps in breast cancer development. Cancer Res (2003) 1.11
Genetic classification of oral and oropharyngeal carcinomas identifies subgroups with a different prognosis. Cell Oncol (2009) 1.10
Detection and clinical relevance of early disseminated breast cancer cells depend on their cytokeratin expression pattern. Breast Cancer Res Treat (2010) 1.09
Distinct functional roles of Akt isoforms for proliferation, survival, migration and EGF-mediated signalling in lung cancer derived disseminated tumor cells. Cell Signal (2011) 1.08
Allelic length of a CA dinucleotide repeat in the egfr gene correlates with the frequency of amplifications of this sequence--first results of an inter-ethnic breast cancer study. J Pathol (2004) 1.08
Prognostic significance of truncating TP53 mutations in head and neck squamous cell carcinoma. Clin Cancer Res (2011) 1.08
Genetic reprogramming of tumor cells by zinc finger transcription factors. Proc Natl Acad Sci U S A (2005) 1.07
High-risk human papillomavirus-positive lung cancer: molecular evidence for a pattern of pulmonary metastasis. J Thorac Oncol (2013) 1.06
A noninvasive genetic screening test to detect oral preneoplastic lesions. Lab Invest (2005) 1.06
Molecular targeted therapies for breast cancer treatment. Breast Cancer Res (2008) 1.03
Gene dosage PCR and fluorescence in situ hybridization reveal low frequency of egfr amplifications despite protein overexpression in invasive breast carcinoma. Lab Invest (2004) 1.03
Second field tumors: a new opportunity for cancer prevention? Oncologist (2005) 1.01
Cytokeratin alteration in oral leukoplakia and oral squamous cell carcinoma. Oncol Rep (2007) 1.01
Time trends in the prevalence of HPV in oropharyngeal squamous cell carcinomas in northern Spain (1990-2009). Int J Cancer (2013) 1.01
Effectiveness of hydroxyapatite-vancomycin bone cement in the treatment of Staphylococcus aureus induced chronic osteomyelitis. Biomaterials (2005) 1.00
Prognostic impact of Cyfra21-1 and other serum markers in completely resected non-small cell lung cancer. Lung Cancer (2002) 1.00
DNA quality assessment for array CGH by isothermal whole genome amplification. Cell Oncol (2007) 0.99
Protein biomarker discovery for head and neck cancer. J Proteomics (2010) 0.99
Cell cycle regulating proteins p21 and p27 in prognosis of oral squamous cell carcinomas. Oncol Rep (2007) 0.98
Immortalization of oral keratinocytes by functional inactivation of the p53 and pRb pathways. Int J Cancer (2010) 0.97
Genome-wide microarray gene expression, array-CGH analysis, and telomerase activity in advanced ovarian endometriosis: a high degree of differentiation rather than malignant potential. Int J Mol Med (2008) 0.97
Molecular analysis of surgical margins in head and neck cancer: more than a marginal issue. Oral Oncol (2010) 0.96
Clinical significance of micrometastatic cells detected by E48 (Ly-6D) reverse transcription-polymerase chain reaction in bone marrow of head and neck cancer patients. Clin Cancer Res (2004) 0.96
Quantitative high-resolution genomic analysis of single cancer cells. PLoS One (2011) 0.96
Using tissue adjacent to carcinoma as a normal control: an obvious but questionable practice. J Pathol (2004) 0.95
Molecular characterization of p16-immunopositive but HPV DNA-negative oropharyngeal carcinomas. Int J Cancer (2013) 0.95
Wait-and-see policy for the N0 neck in early-stage oral and oropharyngeal squamous cell carcinoma using ultrasonography-guided cytology: is there a role for identification of the sentinel node? Head Neck (2002) 0.94
Evaluation of cornulin, keratin 4, keratin 13 expression and grade of dysplasia for predicting malignant progression of oral leukoplakia. Oral Oncol (2009) 0.94
Novel diagnostic modalities for assessment of the clinically node-negative neck in oral squamous-cell carcinoma. Lancet Oncol (2012) 0.93
Status of primary tumour surgical margins in squamous head and neck cancer: prognostic implications. Curr Opin Otolaryngol Head Neck Surg (2007) 0.91
Gene expression profiling in head and neck squamous cell carcinoma. Curr Opin Otolaryngol Head Neck Surg (2010) 0.91
Selective regain of egfr gene copies in CD44+/CD24-/low breast cancer cellular model MDA-MB-468. BMC Cancer (2010) 0.91
Epidermal growth factor receptor expression in high-grade osteosarcomas is associated with a good clinical outcome. Clin Cancer Res (2007) 0.91
Inositol 1,4,5-trisphosphate 3-kinase-A is a new cell motility-promoting protein that increases the metastatic potential of tumor cells by two functional activities. J Biol Chem (2009) 0.90
BRCA1 loss preexisting in small subpopulations of prostate cancer is associated with advanced disease and metastatic spread to lymph nodes and peripheral blood. Clin Cancer Res (2010) 0.90
Circulating invariant natural killer T-cell numbers predict outcome in head and neck squamous cell carcinoma: updated analysis with 10-year follow-up. J Clin Oncol (2012) 0.90
Screening for oral precancer with noninvasive genetic cytology. Cancer Prev Res (Phila) (2009) 0.90
Validation of a gene expression signature for assessment of lymph node metastasis in oral squamous cell carcinoma. J Clin Oncol (2012) 0.90
Assessment and clinical significance of micrometastases in lymph nodes of head and neck cancer patients detected by E48 (Ly-6D) quantitative reverse transcription-polymerase chain reaction. Lab Invest (2003) 0.90
Functional genetic screens identify genes essential for tumor cell survival in head and neck and lung cancer. Clin Cancer Res (2013) 0.89
Genomic profiling identifies common HPV-associated chromosomal alterations in squamous cell carcinomas of cervix and head and neck. BMC Med Genomics (2009) 0.89
Decay-accelerating factor (CD55): a versatile acting molecule in human malignancies. Biochim Biophys Acta (2006) 0.89
Amplifications of the epidermal growth factor receptor gene (egfr) are common in phyllodes tumors of the breast and are associated with tumor progression. Lab Invest (2006) 0.89
Differential Proteomics Identifies Protein Biomarkers That Predict Local Relapse of Head and Neck Squamous Cell Carcinomas. Clin Cancer Res (2009) 0.89
Influence of whole arm loss of chromosome 16q on gene expression patterns in oestrogen receptor-positive, invasive breast cancer. J Pathol (2011) 0.88
Frequent genetic alterations in EGFR- and HER2-driven pathways in breast cancer brain metastases. Am J Pathol (2013) 0.88
No evidence for active human papillomavirus (HPV) in fields surrounding HPV-positive oropharyngeal tumors. J Oral Pathol Med (2013) 0.88
Microarray analysis of bleomycin-exposed lymphoblastoid cells for identifying cancer susceptibility genes. Mol Cancer Res (2006) 0.86
Discordance of genetic alterations between primary head and neck tumors and corresponding metastases associated with mutational status of the TP53 gene. Genes Chromosomes Cancer (2002) 0.86
Treatment response of HPV-positive and HPV-negative head and neck squamous cell carcinoma cell lines. Oral Oncol (2013) 0.86
Genome-wide investigation of multifocal and unifocal prostate cancer-are they genetically different? Int J Mol Sci (2013) 0.85
In vitro and in vivo imaging of cell migration: two interdepending methods to unravel metastasis formation. Semin Cancer Biol (2005) 0.85
DNA-bound platinum is the major determinant of cisplatin sensitivity in head and neck squamous carcinoma cells. PLoS One (2013) 0.85
Molecular screening of oral precancer. Oral Oncol (2013) 0.84
Quantitative molecular detection of minimal residual head and neck cancer in lymph node aspirates. Clin Cancer Res (2003) 0.84
Protein signatures associated with tumor cell dissemination in head and neck cancer. J Proteomics (2011) 0.84
Re: Human papillomavirus DNA and p53 polymorphisms in squamous cell carcinomas from Fanconi anemia patients. J Natl Cancer Inst (2004) 0.84
Intensity-based analysis of dual-color gene expression data as an alternative to ratio-based analysis to enhance reproducibility. BMC Genomics (2010) 0.84
Loss of heterozygosity at 9p and p53 immunopositivity in surgical margins predict local relapse in head and neck squamous cell carcinoma. Int J Cancer (2011) 0.84
Semi-quantitative immunochromatographic test for prostate specific antigen in whole blood: tossing the coin to predict prostate cancer? Eur Urol (2003) 0.83
Identification of lethal microRNAs specific for head and neck cancer. Clin Cancer Res (2013) 0.83
To DNA or not to DNA? That is the question, when it comes to molecular subtyping for the clinic! Clin Cancer Res (2011) 0.83
No evidence for FANCF gene silencing in head-and-neck squamous cell carcinomas. Cell Oncol (2009) 0.82
Comparative evaluation of genetic assays to identify oral pre-cancerous fields. J Oral Pathol Med (2008) 0.82
The expression and action of decay-accelerating factor (CD55) in human malignancies and cancer therapy. Cell Oncol (2006) 0.82